Please assess the completion status of the following clinical trial:

Trial Title: E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have fully completed C07-001 study 12-week treatment period~Exclusion Criteria:~* Patients who terminated early from the C07-001 study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: EXPERIMENTAL): Treatment with eculizumab for patients with PNH who have successfully completed the C07-001 protocol

Based on this trial design, predict the completion outcome and termination type (if applicable).